Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Hodgkin Disease 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Rituximab 4Vincristine 3Prednisone 3Filgrastim 3Etoposide 3Doxorubicin 3Cyclophosphamide 3prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1etoposide phosphate 1deltacortene 1Ultrasonography 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, AIDS-Related × pegylated granulocyte colony-stimulating factor × Clear all
NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
46 enrolled 19 charts
Lymphoid

Lymphoma, AIDS-Related

Data powered by HemOnc (CC BY 4.0) Colophon âš¡